Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Black Diamond Therapeutics (BDTX) Operating Expenses (2018 - 2025)

Black Diamond Therapeutics' Operating Expenses history spans 6 years, with the latest figure at $17.6 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 3.64% year-over-year to $17.6 million; the TTM value through Dec 2025 reached $57.5 million, down 27.04%, while the annual FY2025 figure was $57.5 million, 27.04% down from the prior year.
  • Operating Expenses reached $17.6 million in Q4 2025 per BDTX's latest filing, up from $11.0 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $35.4 million in Q3 2021 to a low of $11.0 million in Q3 2025.
  • Average Operating Expenses over 3 years is $21.6 million, with a median of $18.3 million recorded in 2024.
  • Peak YoY movement for Operating Expenses: skyrocketed 138.47% in 2021, then crashed 39.45% in 2025.
  • A 3-year view of Operating Expenses shows it stood at $35.4 million in 2021, then crashed by 48.32% to $18.3 million in 2024, then dropped by 3.64% to $17.6 million in 2025.
  • Per Business Quant, the three most recent readings for BDTX's Operating Expenses are $17.6 million (Q4 2025), $11.0 million (Q3 2025), and $13.4 million (Q2 2025).